DR. RONALD DANIEL NEUMANN, M.D.
Medical Practice in Bethesda, MD
License number
Maryland D0032096
Category
Medical Practice
Type
Nuclear Imaging & Therapy
Address
Address
2
9000 Rockville Pike Nih Msc 1180, Bethesda, MD 20892
11407 Duryea Dr, Rockville, MD 20854
11407 Duryea Dr, Rockville, MD 20854
Phone
(301) 496-6455
Professional information
Dr. Ronald D Neumann, Bethesda MD - MD (Doctor of Medicine)
Specialties:
Nuclear Medicine
Address:
9000 Rockville Pike, Bethesda 20892
(301) 496-6455 (Phone)
(301) 496-6455 (Phone)
Certifications:
Nuclear Medicine, 1979
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
Yale University
Graduated: 1974
Yale-New Haven Hospital
Yale University
Graduated: 1974
Yale-New Haven Hospital
Ronald Daniel Neumann, Bethesda MD
Specialties:
Nuclear Medicine Specialist
Address:
9000 Rockville Pike, Bethesda, MD 20892
Ronald Daniel Neumann, Bethesda MD
Specialties:
Nuclear Medicine, Clinical & Laboratory Immunology
Work:
National Institutes of Health
10 Ctr Dr, Bethesda, MD 20892
10 Ctr Dr, Bethesda, MD 20892
Education:
Yale University (1974)
Antigen-Specific Composition And In Vivo Methods For Detecting And Localizing An Antigenic Site And For Radiotherapy
US Patent:
5185142, Feb 9, 1993
Filed:
Jul 28, 1989
Appl. No.:
7/386095
Inventors:
Steven M. Larson - Washington DC
Ronald Finn - Bethesda MD
Jorge A. Carrasquillo - Rockville MD
James C. Reynolds - Rockville MD
Ronald D. Neumann - Potomac MD
Martin C. Graham - Larchmont NY
Keith S. Pentlow - Forest Hills NY
Ronald Finn - Bethesda MD
Jorge A. Carrasquillo - Rockville MD
James C. Reynolds - Rockville MD
Ronald D. Neumann - Potomac MD
Martin C. Graham - Larchmont NY
Keith S. Pentlow - Forest Hills NY
Assignee:
The United States of America as represented by the Secretary of the
Department of Health and Human Services - Washington DC
Department of Health and Human Services - Washington DC
International Classification:
A61K 4902, C07K 1500
US Classification:
424 11
Abstract:
A composition comprises an antigen-specific antibody or antigen-binding fragment thereof labeled with Iodine-124 at a site other than, and which does not significantly interfere with, the antibody-antigen binding site. An in vivo method of radiotherapy directed to an antigenic site comprises administering to a subject in need of the therapy an amount of the antigen-specific composition described above effective to attain a reduction of the size of a tumor associated with the antigen. An in vivo method for detecting and localizing an antigenic site in a subject in need of such detection comprises administering to the subject an amount of the antigen-specific composition of the invention effective to localize the antigen-antibody binding site and scanning the subject's body with a positron-emitter detector to attain the localization of the site. An in situ method of radiotherapy directed to an antigenic site in a subject in need of such therapy comprises detecting and localizing the site by the in vivo method described above and thereafter in situ delivering a positron-emitting labeled antibody chelate capable of binding to either the I-124 labeled antibody or fragment thereof, or to the antigen at a site other than the antibody-antigen binding site.